Perlmutter Cancer Center

The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in patients with advanced solid tumors. CPI-0209 is an investigational small molecule inhibitor of the catalytic activity of Enhancer of Zeste Homolog 2 (EZH2), formulated as tablets for oral administration. The study drug CPI-0209 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.